Tumor-associated macrophages (TAM) are an important component of the tumor stroma and exert several tumor-promoting activities. Strongly pro-angiogenic TAMs that reside in hypoxic tumor areas highly express macrophage mannose receptor (MMR, CD206) 
Introduction
Tumors harbor dynamic microenvironments in which cancer cells are intimately associated with nontransformed host cells. The tumor-associated stroma is considered to play an important role during tumor growth, influencing phenomena such as angiogenesis, metastasis, and immune suppression (1) . As such, the stroma forms an attractive target for diagnostic and therapeutic applications (2) . Different myeloid cell types are important components of the tumor stroma (3, 4) . In particular, macrophages are often found to infiltrate tumors in high numbers (5-7). We previously characterized tumor-associated macrophages (TAM) in different preclinical tumor models (8) . Extensive gene and protein expression analysis led us to identify distinct TAM subsets, termed MHC II hi and MHC II low TAMs. Interestingly, these subsets reside in different intratumoral microenvironments and differentially express molecules involved in inflammation, chemotaxis, and angiogenesis. MHC II low TAMs are mainly located in hypoxic tumor areas and are strongly proangiogenic. In contrast, MHC II hi TAMs are found in normoxic/ perivascular regions and are significantly less pro-angiogenic. Besides MHC II, we identified several membrane markers that can distinguish between these TAM subpopulations. This included the macrophage mannose receptor (MMR, CD206), an endocytic C-type lectin receptor known for its prominent expression on alternatively activated macrophages, which is consistently upregulated on MHC II low TAMs in all tumor models studied (8) . These observations make MMR an attractive marker for targeting the MHC II low hypoxic TAM subset in vivo.
Antibody-based tumor-targeting strategies are widely explored (9, 10) . Antibodies can be used for tumor imaging or delivering therapeutic agents to tumor cells. However, limitations of conventional antibodies include a poor penetration of solid tumors and high Fc-mediated aspecific binding, highlighting the need for smaller and more specific binding units. Nanobodies (Nb) are the smallest available antigenbinding fragments (15 kDa) derived from Camelid heavychain-only antibodies (11, 12) . Nbs are stable, soluble, have a high affinity, and show an increased tissue penetration, making them particularly suitable for tumor targeting (13, 14) . Previous work showed that a Nb-conjugate can efficiently target and kill cancer cells harboring a model antigen (15, 16) . In addition, employing pinhole SPECT/micro-CT technology, 99m Tc-labeled Nbs have been successfully used as probes for cancer cell markers in tumor imaging (17) (18) (19) (20) and for dendritic cell markers to image their in vivo biodistribution (21) . Indeed, because of their small size, unbound Nbs are rapidly eliminated by renal clearance, resulting in high signal-to-noise ratios. As a result, imaging can be carried out as early as 1 hour postinjection of the nanobody probe, enabling the use of short-lived radioisotopes with a clear benefit for the patient (22) .
In this article, we describe the production, selection, and characterization of Nbs against MMR. 
Materials and Methods

Mice and cell lines
Animal studies followed the guidelines of the institutional review board. Female Balb/c and C57BL/6 mice were from Harlan. C57BL/6 MMR-deficient, CCR2-deficient, and MMTVPyMT mice were provided by Etienne Pays (Universit e Libre de Bruxelles), Frank Tacke (Aachen University), and Massimiliano Mazzone (KU Leuven), respectively. The Balb/c mammary adenocarcinoma TS/A and 3LL-R clone of the C57BL/6 Lewis Lung carcinoma (8) were injected subcutaneously (s.c.) in the flank or in the fat pads (3 Â 10 6 cells). Within 12 to 14 days after inoculation, TS/A and 3LL-R tumor-bearing mice were subjected to imaging. MMTV-PyMT mice bearing macroscopic tumors were consecutively imaged with distinct tracers 48 to 72 hours apart. Tumor dissection and flow cytometry were carried out 96 hours after the last scan.
Tumor preparation and flow cytometry
Preparation of tumor single-cell suspensions has been described previously (8) . Antibodies used for stainings were anti-CD11b(M1/70)/PE-Cy7, anti-Ly6G(1A8)/FITC (Becton Dickinson Biosciences), anti-IA/IE(M5/114.15.2)/ PerCPCy5.5 (Biolegend), anti-Ly6C(ER-MP20)/AF647, anti-MMR(MR5D3)/PE, and anti-F4/80(CI:A3-1)/PE (Serotec). To prevent aspecific binding, rat anti-mouse CD16/CD32 (2.4G2; Becton Dickinson Biosciences) was used. Nanobodies were labeled using the Alexafluor488 or Alexafluor647
Protein Labeling Kit (Invitrogen) according to the manufacturers' instructions.
Immunofluorescence stainings
Mice were injected intravenously with 500 mg Alexa-fluor647-labeled Nbs and intraperitoneally with 80 mg/kg pimonidazole [hypoxyprobe-1, HPI, Inc.] for hypoxia stainings. Two hours later, tumors were fixed in 4% paraformaldehyde, rehydrated overnight (20% sucrose), and sectioned (5-mm-thick slices). Antibodies used were: rat anti-F4/80/alexa-fluor488 (CI: A3-1, Serotec), F(ab') 2 donkey anti-rabbit/Cy3 JacksonImmuno). Pictures were acquired with a Plan-Neofluar 10Â/ 0.30 or 20Â/0,50 (Carl Zeiss) objective on a Zeiss Axioplan2 microscope with an Orca-R2 camera (Hamamatsu) and Smartcapture 3 software (Digital Scientific, United Kingdom).
Generation of mono-and bivalent nanobodies
The anti-MMR Nb clones 1 and 3 were isolated from an immune Nb phage-display library (23, 24 ). An alpaca (Vicugna pacos) was immunized weekly with 100 mg MMR extracellular domain (R&D Systems) 6 times. Peripheral blood lymphocyte mRNA was converted to cDNA, from which Nb-coding sequences were amplified and ligated onto the pHEN4 phagemid vector (25) . Using M13K07 helper phages, the Nb library was expressed on phages, and specific Nb-phages were enriched by 3 rounds of selection on microtiter plates (Nunc) coated with recombinant MMR. Individual colonies were screened in ELISA for antigen recognition and sequenced. The Nb genes of clones 1 and 3 were recloned into the vector pHEN6 to encode a C-terminal His 6 tag (25) . Nanobody Nb BCII10 (25) was used as the negative control.
Bivalent Nbs were generated by attaching a linker sequence 3 0 of the anti-MMR Nb clone1 VHH sequence using primer biNbF and primers biNbG4SR, biNbg2cR, and biNbIgAR (Supplementary Table S1 ), which code for a (G 4 S) 3 (GGGGSGG-GGSGGGGS), llama IgG2 hinge (AHHSEDPSSKAPKAPMA), or human IgA hinge (SPSTPPTPSPSTPPAS) linker, respectively. PCR fragments were inserted 5 0 of the a-MMR cl1 gene or the BCII10 gene in the pHEN6 vector.
Periplasmic expression and purification of mono-and bivalent Nbs was carried out as described previously (19) .
99m Tc-Nanobody labeling, pinhole SPECT-micro-CT imaging, and biodistribution analysis Nanobodies were labeled with 99m Tc at their hexahistidine tail and subjected to quality assurance, as described previously (17, 19, 21) . Mice were intravenously injected with 100 to 200 mL of 45 to 155 MBq of 99m Tc-labeled Nb, with or without an excess of bivalent unlabeled Nanobody. At 60 or 180 minutes postinjection, anesthesia, micro-CT, and pinhole SPECT-imaging were carried out as described previously (19) . Image viewing was conducted using AMIDE Medical Image Data Examiner software. High-resolution image 3-dimensional (3D)-reconstructions were generated using OsiriX Imaging Software. At 30 minutes after initiating micro-CT/SPECT acquisition, organs were removed and weighed, and radioactivity was measured using an automated g-counter (Cobra II Inspector 5003; Canberra-Packard). Tissue and organ uptake was calculated as the percentage of injected activity per gram tissue (%IA/g), corrected for decay.
Statistics
Statistical analyses were conducted using the Student's t test assuming unequal variances. Because multiple comparisons are made (9-10 different organs), the P values of the Student's t-test were adjusted by Holm's procedure (26) . The R environment (27) Generation and characterization of a-MMR nanobodies Nanobodies were raised against the recombinant extracellular domain of MMR and, after screening of an immune phage library, 2 MMR-specific Nb clones were isolated: Nb cl1 and cl3. The binding characteristics of the anti-MMR Nbs were compared using surface plasmon resonance (SPR) measurements (Supplementary Table S2 and Supplementary Fig. S3 ). Nb cl1 showed an 8-fold higher apparent affinity for immobilized recombinant MMR compared with Nb cl3 (K D ¼ 2.31 Â 10 À8 vs. 1.91 Â 10 À7 mol/L, respectively). In addition, SPR competition studies showed that pretreatment with cl1 does not preclude cl3 binding and vice versa, indicating that anti-MMR Nbs cl1 and cl3 bind to non-overlapping epitopes (Supplementary Fig. S3 ). First, we investigated whether the a-MMR Nb cl1 could bind surface-expressed MMR on TAMs ex vivo. In this regard, flow cytometric analyses were carried out using fluorescently labeled Nb cl1 on subcutaneous TS/A and 3LL-R tumor single-cell suspensions (Fig. 1) . As a negative control Nb, we consistently used Nb BCII10 (25) . The a-MMR Nb cl1 was found to bind to a subset of CD11b þ cells, but not to CD11b Fig. 1D , gate 3), expressing high levels of CD11c and costimulatory molecules (data not shown). These results are, therefore, in line with our observations using a-MMR monoclonal antibodies ( Supplementary Fig. S1 ).
Finally, a-MMR Nb cl1 bound to myeloid subsets in healthy organs of tumor-bearing mice, an important example being the liver, wherein distinct macrophage subpopulations were stained in single-cell suspensions ( Supplementary Fig. S4 ).
Assessment of the biodistribution and specificity of a-MMR nanobodies in naive mice using pinhole SPECT/ micro-CT analysis and ex vivo dissection Next, we assessed whether the a-MMR Nbs could be used for targeting and imaging of MMR-expressing cells in vivo. First, this was investigated in naive mice, where MMR can be expressed on tissue macrophages, dendritic cells, and subsets of hepatic and lymphatic endothelial cells (29, 30) . Therefore, 99m Tc-labeled a-MMR Nb cl1, a-MMR Nb cl3, and control Nb BCII10 were injected intravenously in naive C57BL/6 mice. One hour postinjection, total-body scans were acquired using pinhole SPECT/micro-CT ( Fig. 2A ; only shown for cl1). In addition, mice were sacrificed and the biodistribution was assessed by measuring radioactivity in various dissected organs, which was expressed as injected activity per gram tissue (%IA/g; Supplementary Table S3) . Besides intense staining of the kidneys and bladder, consistent with the rapid clearance of Nb, an increased retention of the a-MMR Nb, but not the control Nb BCII10, was measured in several organs and tissues, including cardiac muscle, bone marrow, spleen, and liver, with the latter two showing the most intense signals (Supplementary Table S3 ; Fig. 2A ). In wild-type (WT) mice, a-MMR Nb cl1 showed a clearly higher uptake than a-MMR Nb cl3 (Supplementary Table S3 ). Importantly, in vivo retention of Nb cl1 and cl3 is receptor-specific as only background-level tracer uptake is seen in organs of MMR-KO mice (Supplementary Table S3 , Fig. 2A) . Therefore, the a-MMR Nbs have a high in vivo specificity and can efficiently target organs such as the liver and spleen. Given the higher affinity of Nb cl1 for recombinant MMR and the higher in vivo uptake, we chose this Nb as lead compound for further research.
Tumor-targeting potential of a-MMR Nb cl1
Next, we investigated whether a-MMR Nb cl1 could be used for TAM-targeting in vivo. Therefore, 99m Tc-labeled a-MMR Nb cl1 was injected intravenously in TS/A and 3LL-R s.c. tumorbearing mice and SPECT/micro-CT and ex vivo dissection analyses were carried out.
99m Tc-labeled Nb BCII10 was injected as negative control. Interestingly, both TS/A and 3LL-R tumors showed a clear uptake of a-MMR Nb, which Cancer Research 4168 was significantly higher than tumor uptake of Nb BCII10 (Fig.  2B-C) . These findings were confirmed through ex vivo dissection analysis: TS/A tumor uptake was 3.02 AE 0.10%IA/g for a-MMR Nb and 0.40 AE 0.03%IA/g for Nb BCII10; 3LL-R tumor uptake was 3.02 AE 0.19%IA/g for a-MMR Nb and 0.74 AE 0.03%IA/g for Nb BCII10 (Table 1) . To further ascertain the specificity of tumor uptake, 3LL-R tumors were grown in MMR-KO mice. In these animals, 3LL-R tumors grew progressively and the distinct TAM subsets remained present and were MMR negative, as assessed by flow cytometry (Supplementary Fig.  S5 ). Importantly, tumor uptake of a-MMR Nb was reduced by 10-fold (0.33 AE 0.03%IA/g; Table 1 ), showing its dependence on MMR expression by host cells.
a-MMR Nb cl1 targets hypoxic TAMs in vivo
Having established that a-MMR Nb cl1 specifically targeted MMR þ cells in tumors, we aimed to ascertain whether this was due to TAM targeting. Previous work showed that CCR2-deficiency can result in a significant decrease in TAM infiltration with only a minimal effect on tumor growth, resulting from the compensatory influx of tumor-promoting neutrophils (31, 32) . To investigate whether CCR2-deficiency affected the numbers of TAMs and, in particular, MHC II low TAMs in our model, flow cytometric analyses were carried out on single-cell suspensions of equally sized s.c. 3LL-R tumors grown in WT or CCR2-KO mice. This showed that CCR2-deficiency led to a dramatic reduction in the number of MHC II low TAMs, while infiltration of Ly6G þ MMR À neutrophils was significantly increased ( Fig. 3A; Supplementary Fig. S6 ). Next, we compared the tumor-uptake of 99m Tc-labeled a-MMR Nb cl1 injected in WT with those in CCR2-KO 3LL-R tumor-bearing mice.
99m Tclabeled a-MMR Nb showed a similar biodistribution in the organs/tissues of CCR2-KO compared with WT tumor bearers (Supplementary Table S4 ). Importantly however, uptake of 99m Tc-labeled a-MMR Nb was significantly reduced in CCR2-KO tumors: 2.97 AE 0.22%IA/g in WT compared with 1.83 AE 0.1%IA/g in CCR2-KO tumors (Fig. 3B ). This indicates that TAMs residing in solid tumors are indeed targets of a-MMR Nbs in vivo. Because MHC II low MMR þ TAM have been reported to associate with hypoxic regions (8), we next assessed whether a-MMR Nbs preferentially label hypoxic TAM in vivo. In this regard, AF647-coupled a-MMR Nbs were injected intravenously in s.c. 3LL-R WT or MMR-KO tumor-bearing mice. Two hours later, tumors were collected, sectioned, and stained for the hypoxia marker pimonidazole (hypoxyprobe) and the macrophage marker F4/80. Interestingly, AF647 fluorescence almost completely co-localized with F4/80 staining in WT tumors, but was absent from MMR-KO tumors (Fig. 3C ). In addition, the majority of AF647(bright) cells were located in hypoxic areas and stained with pimonidazole ( Fig. 3C-D) . These results convincingly show that a-MMR Nbs can target hypoxic tumor regions in vivo, where they bind to the residing MMR þ macrophages. Strategies for increasing the tumor-to-tissue ratio of 99m Tc-labeled a-MMR Nb cl1 A methodology for the specific in vivo targeting of a tracer to TAMs, but not to other sites in the body, could be of important diagnostic and therapeutic significance. However, both in the TS/A and 3LL-R models, 99m Tc-labeled anti-MMR Nb accumulates to a higher extent in liver and spleen as compared with the tumor. Therefore, we aimed to minimize binding of labeled (Fig. 4A) . First, aMMR-aMMR bivalent Nbs were made by cloning 3 different peptide linkers with increasing proline content (glycine-serine linker, part of the llama IgG2c hinge or part of the human IgA hinge) between 2 Nb cl1 sequences. All of these bivalent Nbs showed a 5-fold higher avidity compared with the monovalent Nb cl1, which can be largely attributed to a 3-fold increase in K D (Supplementary Table S2 ), and displayed a very similar in vivo biodistribution (Supplementary Table S5 ). In addition, using the llama IgG2c linker, aMMR-BCII10 bispecific Nbs and BCII10-BCII10 bivalent Nbs were generated and their in vivo biodistribution was evaluated in TS/A and 3LL-R tumor-bearing mice. Interestingly, aMMR-BCII10 and especially aMMR-aMMR Nbs showed a significantly enhanced targeting of liver and spleen, but a dramatically reduced targeting of tumor, compared with monovalent a-MMR Nbs (Fig. 4B) . Therefore, these bivalent Nbs seem to possess desirable features to efficiently block extratumoral binding sites while preserving intratumoral binding sites. To test this hypothesis, we coinjected 99m Tc-labeled monovalent a-MMR Nb with a 20-fold molar excess of unlabeled bivalent aMMRaMMR Nb and assessed the specific uptake of labeled Nb in distinct organs. While the retention of monovalent 99m Tclabeled a-MMR Nb is reduced in all organs to the aspecific background level seen with Nb BCII10, the uptake in tumors is TcaÀMMR Nb þ cold Nb Ã , P < 0.05; ÃÃ , P < 0.01; ÃÃÃ , P < 0.001. LN, lymph node.
only slightly diminished (Fig. 4C) . As a result, the tumor-totissue ratio of labeled a-MMR Nb is dramatically increased and tracer uptake is highest in the tumor. This allowed the tumor to be clearly distinguishable in SPECT/micro-CT imaging of mice bearing subcutaneous tumors (Fig. 5A, B , Supplementary Video S1). Importantly, very similar imaging data were obtained when TS/A tumors were grown orthotopically in the mammary fat pad ( Fig. 5C-D; Supplementary Video S2) , for which the presence of the 2 main TAM subsets was reported before (8) . Finally, imaging studies were carried out in transgenic MMTV-PyMT mice, which spontaneously develop mammary tumors (33) . In this regard, a mouse bearing multiple macroscopic tumors was consecutively imaged (48-hour intervals to allow complete elimination and decay of the 99m Tc tracer) with either 99m Tc-labeled a-MMR Nb, 99m Tc-labeled BCII10 Nb, or 99m Tc-labeled a-MMR Nb coinjected with unlabeled bivalent aMMR-aMMR Nb. When 99m Tc-labeled a-MMR Nb was injected alone, tumors were not easily distinguishable due to high extratumoral uptake (Fig. 6A) . However, coinjecting unlabeled bivalent aMMR-aMMR Nb minimalised extratumoral Nb retention and resulted in tracer uptake in the most prominent macroscopic nodules as seen via highresolution 3D CT reconstructions ( Fig. 6B; Supplementary  Video S3) . Notably, fluorescence-activated cell-sorting (FACS) analysis showed that, for all 3 selected tumors highlighted in Fig. 6B , distinct TAM subpopulations were present, whereby MMR expression was highest on the MHC II low TAMs (Fig. 6C) .
Effect of mono-and bivalent a-MMR Nb cl1 on immune cell activation Monoclonal anti-MMR antibodies are known to potentially activate macrophages and DCs (34) . To assess whether monoor bivalent a-MMR Nb cl1 elicits a response, Nbs were added in varying concentrations to bone-marrow-derived DCs (BMDC) or macrophages (BMDM) in vitro or were injected at a high dose in vivo. Monovalent a-MMR Nbs did not alter cytokine/ chemokine production by BMDCs nor BMDMs in vitro, with or without LPS stimulation (Supplementary Fig. S7 ). With the highest concentration of bivalent Nb (40 mg/mL), we observed a small, but significant, increase in TNF production by DCs and TNF and IL1Ra production by macrophages in vitro. Importantly however, the highest in vivo dose of Nb used in this study (5 mg monovalent Nb þ 200 mg bivalent Nb) did not induce any significant increase in the serum cytokine levels, both for naive and tumor-bearing mice (Supplementary Fig.  S8 ). Overall, we conclude that anti-MMR Nbs are innovative tools for the targeting and imaging of hypoxic MMR þ TAMs without the risk of inducing overt innate immune responses in vivo.
Discussion
Until now, antibody-based tumor-targeting approaches have mostly been directed against antigens expressed on cancer cells (10) . However, the antigenic profile of cancer cells can be unstable and depends on the cancer type. In addition, tumors contain a large stromal compartment, which includes myeloid cells such as macrophages (35) . Stromal cells might provide a good alternative for tumor-targeting, because their antigenic profile is more stable and might be similar across different cancer types. Our previous work indicated MMR as an interesting marker for targeting the most M2-oriented (and potentially most tumor-promoting) macrophage subset in tumors (8) . In this article, we describe the production of MMR-specific nanobodies and show that they can be used for efficient in vivo targeting and imaging of TAMs in solid tumors.
We describe 2 a-MMR Nbs, which bind to different epitopes and have distinct affinities and in vivo targeting efficiencies. The a-MMR Nb cl1 was selected as the lead compound and its tumor-targeting potential was first examined in mice bearing subcutaneous 3LL-R lung or TS/A breast carcinoma tumors. For both models, ex vivo dissection showed that the a-MMR Nb had a tumor uptake of approximately 3%IA/g. Previous studies using nanobodies for the targeting of antigens (CEA, HER-2) on tumor xenografts, in which all cancer cells ectopically express the antigen, showed tumor uptake levels in the same range (15, 16) . Further, these amounts were sufficient to almost completely eradicate tumors in an antibody-dependent enzyme prodrug therapy approach (16) . We, thus, conclude that a-MMR Nb efficiently targeted solid tumors.
To investigate whether nanobody targeting was receptorspecific, we compared the tumor uptake of a-MMR Nb with that of Nb BCII10, and, more stringently, we compared the uptake of a-MMR Nb in tumors from WT with those in MMR-KO mice. Together, these data convincingly showed that in vivo targeting of the a-MMR Nb is MMR-specific. In tumor singlecell suspensions, a-MMR Nbs primarily bound to TAMs, indicating that this was also one of their targets in vivo. However, we could not exclude the potential targeting of other MMR þ cells in intact tumors. Therefore, we compared the tumor retention of a-MMR Nb injected in WT or CCR2-KO tumor-bearing mice. The 3LL-R tumors in CCR2-KO mice contained significantly lower TAM numbers as compared with WT tumors, and showed a significant reduction in a-MMR Nb uptake, which recommends TAM targeting. Moreover, AF647-labeled a-MMR Nb injected in tumor-bearing mice mainly stained MMR Finding tumor-specific markers for antibody-based targeting remains a daunting task. This is especially true when targeting the tumor stroma, because stromal antigens are typically not restricted to tumors. In this regard, a-MMR Nbs targeted, to a higher extent, the liver and spleen of mice bearing subcutaneous tumors. This may hamper the usefulness of these tools in both diagnostic and therapeutic applications. Importantly however, we describe a novel approach to reduce the targeting of tracers to healthy organs to background levels, while preserving an efficient targeting of the tumor. Indeed, coinjecting an excess of unlabeled bivalent a-MMR Nb blocked all extratumoral sites, while only slightly affecting tumor-specific tracer uptake. This is a result of a bivalent Nb's higher uptake in extratumoral organs such as the liver and spleen (probably explained by a higher avidity for aMMR-aMMR Nb and/or increased in vivo retention due to larger dimensions for aMMR-aMMR and aMMR-BCII10), coupled to a low accumulation in the tumor (probably due to poor tumor penetration). Interestingly, modeling studies have indicated that intermediate-sized targeting agents ($25 to 30 kDa) have the lowest tumor uptake levels among a spectrum of tumortargeting polypeptides of various sizes (37) . Bivalent Nbs, which are 30 kDa, therefore seem to follow this rule and have a low tumor uptake. Similar observations were made with DARPins, which are similar in size to Nbs (15 kDa), and for which fusion of 2 DARPins results in a significantly lower tumor uptake (38) .
We believe that the strategy of co-injecting bivalent cold a-MMR Nb to reduce extratumoral tracer uptake could be translatable to the clinical setting. Preloading therapies, where an excess of cold antibody is injected in patients, are already being carried out. In antibody-based radioimmunotherapy of non-Hodgkin lymphoma, excess amounts of unlabeled anti-CD20 antibody is predosed to patients before injection of 90 Yor 131 I-conjugated anti-CD20 antibody (39) , resulting in increased tracer uptake in tumors and reduced uptake in extratumoral organs such as the spleen. However, determining the optimal cold dose for individual patients is not straightforward because the cold antibody can compete with labeled antibody for free antigen sites in the tumor (40, 41) . The monovalent-labeled-bivalent-cold Nb approach described here seems an attractive alternative, because bivalent Nbs do not efficiently compete for free binding sites in the tumor, while they block extratumoral sites much more efficiently.
Because TAMs are found to be a major stromal component in many cancer types, a-MMR Nbs could potentially be used for targeting a variety of unrelated tumors. We have successfully used this approach for the subcutaneous 3LL-R lung carcinoma model, the subcutaneous and orthotopic TS/A breast carcinoma model, and for the spontaneous MMTV-PyMT breast carcinoma model. Coupled to our methodology of restricting extratumoral tracer uptake, this could now provide novel and attractive diagnostic or therapeutic opportunities. Clear examples would be diagnostic tumor imaging and the noninvasive quantification of TAMs or specific TAM subsets inside any given tumor, which could be of prognostic value. Further, as a-MMR Nbs can penetrate hypoxic areas where the majority of MHC II low /MMR þ TAMs reside, this might provide a new avenue for visualizing hypoxic regions within the tumor, and may be potentially relevant for guided radiotherapy (42) . In addition, radioimmunotherapy might be the most promising therapeutic application for these Nbs, because coupling of Nbs to proteins (e.g., toxins or prodrugconverting enzymes; ref. 43) , might reduce the tumor-targeting efficiency due to a size increase. As a cautionary note, engagement of MMR could potentially trigger cytokine/ chemokine release by DCs and macrophages (34, 44) . However, our results did not show an overt cytokine/chemokine response after in vivo administration of high doses of monoand bivalent a-MMR Nb.
In addition, MMR is a widely used marker for human M2 macrophages (45) (46) (47) , which is expressed on TAMs from human tumors. Co-culture of human macrophages and ovarian cancer cells induces a strong upregulation of MMR expression (48) . Further, Allavena and colleagues have shown that MMR is widely expressed on TAMs isolated from ovarian cancer patients, and that its engagement by tumor mucins can induce an immune-suppressive phenotype (44) . In addition, our ongoing preliminary studies show that, in human breast cancer samples, MMR þ TAMs are clearly detected and, interestingly, are enriched in fibrotic foci, which are known to be a marker for intratumoral hypoxia and correlate with a poor prognosis (data not shown; ref. 49 ). However, it remains to be tested whether MRC1 þ TAMs carry out the tumor-promoting, pro-angiogenic functions in human tumors as reported previously in murine tumors.
In conclusion, our work indicates that, in preclinical models, TAM subsets can be efficiently targeted in vivo using nanobodies against MMR. In addition, we provide a methodology to restrict tracer uptake to the tumor. This could form the basis for developing novel imaging and therapeutic applications for the diagnosis and treatment of cancer. 
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